Detail Information of Exogenous Modulation
General Information of Drug Transporter (DT) | |||||
---|---|---|---|---|---|
DT ID | DTD0124 Transporter Info | ||||
Gene Name | SLC18A3 | ||||
Transporter Name | Vesicular acetylcholine transporter | ||||
Gene ID | |||||
UniProt ID | |||||
Exogenous factors (drugs, dietary constituents, etc.) Modulation of This DT (EGM) | |||||
---|---|---|---|---|---|
Chemical Compound |
|||||
Benzo(a)pyrene |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Benzo(a)pyrene affects the methylation of SLC18A3 promoter | [8] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
Benzo(a)pyrene results in increased methylation of SLC18A3 5' UTR | [8] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
CGP 52608 |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
CGP 52608 promotes the reaction RORA protein binds to SLC18A3 gene | [9] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
potassium perchlorate |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
potassium perchlorate results in decreased expression of SLC18A3 mRNA | [5] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
Raloxifene Hydrochloride |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Raloxifene Hydrochloride co-treated with ESR2 protein results in decreased expression of SLC18A3 mRNA | [10] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
sodium arsenite |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
sodium arsenite results in decreased expression of SLC18A3 mRNA | [11] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
Tamoxifen |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Tamoxifen co-treated with ESR2 protein results in decreased expression of SLC18A3 mRNA | [10] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
Approved Drug |
|||||
Valproic Acid |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Valproic Acid affects the expression of SLC18A3 | [4] | |||
Potassium perchlorate |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Potassium perchlorate inhibits the expression of SLC18A3 | [5] | |||
Testosterone |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Testosterone inhibits the expression of SLC18A3 | [6] | |||
Drug in Phase 3 Trial |
|||||
Triclosan |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Triclosan increases the expression of SLC18A3 | [7] | |||
Investigative Drug |
|||||
Vesamicol |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Vesamicol inhibits the activity of SLC18A3 | [1], [2], [3] | |||
Cell System |
Rat adrenal chromaffin cells (PC12)-VACHT | ||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.